July 1, 2019 News by Mary Chapman PathMaker Neurosystems Wins France’s Top Prize for Innovation for Spasticity Treatment The developer of an innovative, first-in-class, noninvasive device for the treatment of spasticity in multiple sclerosis (MS) and other conditions has won the 2019 CCI France International Trophy for Innovation. PathMaker Neurosystems was selected from a list of eight finalist companies, which were distinguished among 150 nominees…
February 12, 2019 News by Alice Melão, MSc Direct Nerve Stimulation Using MyoRegulator System Seen to Reduce Spasticity in Mice with Spinal Injury Treatment with PathMaker Neurosystems’ anodal trans‐spinal direct current stimulation (tsDCS), a non-invasive direct nerve stimulation tool called MyoRegulator, was found to effectively ease spasticity in mice with spinal cord injury, a study reports. A link between the ability to control muscle contraction and the levels of a specific neuronal…
January 11, 2019 News by Alice Melão, MSc WeHealth, PathMaker Collaborating to Develop MyoRegulator as Noninvasive Treatment for Spasticity WeHealth by Servier and PathMaker Neurosystems have established a new partnership to develop and commercialize the first neuromodulation technology for noninvasive treatment of spasticity, the companies announced. The agreement establishes an exclusive worldwide distribution arrangement, except for the U.S. and Japan, for PathMaker’s MyoRegulator. The MyoRegulator uses two pairs of…
June 4, 2018 News by Patricia Silva, PhD PathMaker Neurosystems, Developing MyoRegulator for Spasticity, Named Startup of Year at French-American Business Gala PathMaker Neurosystems, which specializes in non-invasive devices to treat chronic neuromotor disorders, won the 2018 French-American Business (FAB) Award in the startup/small company category. PathMaker, based in Boston, is developed and testing MyoRegulator, a potential treatment for muscle spasticity in people with multiple sclerosis (MS), cerebral palsy and other chronic conditions.
January 25, 2017 News by Patricia Silva, PhD PathMaker, French Institute to Team on MyoRegulator Neuro-stimulation Clinical Trials PathMaker Neurosystems and the Brain and Spine Institute (ICM) in Paris will collaborate on human clinical trials to secure CE Mark clearance for PathMaker’s MyoRegulator PM-2200, a noninvasive neurotherapy technology to treat conditions linked to neural pathway disruption, including multiple sclerosis (MS). CE Mark — which stands for “Conformité Européenne,” or European Conformity…
October 6, 2016 News by Patricia Silva, PhD PathMaker Wins Innovation Prize for Neurotherapies to Treat Spasticity, Muscle Weakness PathMaker Neurosystems is the winner of the Universal Biotech Innovation Prize 2016 for its innovative, non-invasive neurotherapy technologies to treat conditions linked to neural pathway disruption, including multiple sclerosis (MS). The selection was announced at Innovation Days, an international event honoring the best in the life sciences and held in Paris on Oct. 3–4. Launched in 2009 by a…
April 11, 2016 News by Margarida Azevedo, MSc PathMaker Launches Clinical Trial of MyoRegulator to Treat Spasticity, Common in MS PathMaker Neurosystems, Inc., recently announced the launch of an Institutional Review Board (IRB)-approved clinical trial, in partnership with Northwell Health (formerly North Shore-LIJ Health System) and The Feinstein Institute for Medical Research, to evaluate the safety and efficacy of MyoRegulator for the treatment of spasticity, one of the most common symptoms in multiple sclerosis…
